Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00724568 · ClinicalTrials.gov registry record · Phase 1
Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma
A Phase 1 study, sponsored by University of Michigan Rogel Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 74
- Enrollment target
NCT00724568 is a Phase 1 study that has completed, run by University of Michigan Rogel Cancer Center. The registered enrollment target is 74 participants.
The verdict
NCT00724568, a Phase 1 study, has completed, sponsored by University of Michigan Rogel Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 74 participants
- Enrollment target
Study Summary
This research study is evaluating an investigational combination of four drugs called Revlimid® (lenalidomide), Velcade® (bortezomib), Dexamethasone and Doxil® (RVDD) as a possible treatment for newly diagnosed multiple myeloma.
Interventions
- DRUG Dexamethasone
- DRUG Lenalidomide
- DRUG Doxil
- DRUG Bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 74 participants |
| Start Date | 2008-05 |
| Est. Completion | 2014-09-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00724568
The ClinicalTrials.gov registry entry for NCT00724568 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 74 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan Rogel Cancer Center, which has 292 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Dexamethasone is the first listed.
NCT00724568 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00724568 about?
NCT00724568 is a clinical study titled "Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma". This research study is evaluating an investigational combination of four drugs called Revlimid® (lenalidomide), Velcade® (bortezomib), Dexamethasone and Doxil® (RVDD) as a possible treatment for newly diagnosed multiple myeloma.
What is the current status of trial NCT00724568?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 74 participants. The study started on 2008-05. Estimated completion is 2014-09-03.
What interventions are being tested in trial NCT00724568?
The interventions under investigation include: Dexamethasone (DRUG), Lenalidomide (DRUG), Doxil (DRUG), Bortezomib (DRUG).
Who is sponsoring clinical trial NCT00724568?
This trial is sponsored by University of Michigan Rogel Cancer Center, which has 292 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.